Navigation Links
BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
Date:9/8/2010

LYNBROOK, N.Y., Sept. 8 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming Rodman & Renshaw 12th Annual Healthcare Conference on Wednesday, September 15, 2010, at 9:35am EDT.

A live webcast of the presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at http://www.biospecifics.com, or you may use the link: http://www.wsw.com/webcast/rrshq18/bstc.

About BioSpecifics Technologies Corp.BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for eleven clinical indications, three of which include: Dupuytren's contracture, Peyronie's disease, and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium markets XIAFLEX in the U.S. for the treatment of Dupuytren's contracture. Pfizer, Inc. is responsible for marketing XIAFLEX in Europe. More information about BioSpecifics may be found on its website at http://www.biospecifics.com. Contact:BioSpecifics Technologies Corp.Thomas L. Wegman, President(516) 593-7000thomas_wegman@biospecifics.com
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
2. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
3. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
4. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
5. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
6. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
7. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
8. BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
9. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
10. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
11. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017  Vermillion, Inc. (NASDAQ: VRML), a bio-analytical ... its results for the fourth quarter and full ... marked a pivotal year for us with our ... distribution agreements, major reimbursement progress with Medicare, positive ... In addition we cleared our 2 nd ...
(Date:3/29/2017)... "Surging application of gesture control features in ... expected to drive the growth of gesture recognition and ... is expected to be worth USD 18.98 billion by ... and 2022. The touchless sensing market is expected to ... a CAGR of 17.44% between 2017 and 2022. Gesture ...
(Date:3/29/2017)... , March 29, 2017 WuXi Biologics, ... company dedicated to biologics and a WuXi AppTec ... 2017 Asia-Pacific Best Bioprocessing Excellence Award from IMAPAC, ... Excellence Awards aims to recognize outstanding leaders and ... Featuring top bioprocessing and biomanufacturing experts in the ...
(Date:3/29/2017)... ... March 29, 2017 , ... (March 29, 2017) — ... approved as an active member of the Mexican Direct Selling Association A.C. ... consumers in relationship marketing. This professional organization fosters loyal and fair competition among ...
Breaking Biology Technology:
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
Breaking Biology News(10 mins):